Trials / Terminated
TerminatedNCT00134953
Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 24 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- —
Summary
This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with mild cognitive impairment (MCI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivastigmine |
Timeline
- Start date
- 2003-01-01
- Completion
- 2004-05-01
- First posted
- 2005-08-25
- Last updated
- 2007-12-17
Source: ClinicalTrials.gov record NCT00134953. Inclusion in this directory is not an endorsement.